Zhengye Biotechnology Holding Ltd(ZYBT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-12-31.

Zhengye Biotechnology Holding Ltd (ZYBT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ZYBT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 8 institutional filers currently hold this stock. Based on the latest XBRL financial filings (FY 2025), Zhengye Biotechnology Holding Ltd reports quarterly revenue of $16.6M, net income of $-10.0M, an operating margin of -60.6%. Top institutional holders of ZYBT by reported 13-F value include XTX Topco Ltd, GEODE CAPITAL MANAGEMENT, WINTON GROUP Ltd, based on the most recent SEC filings. ZYBT trades on the Nasdaq exchange and files with the SEC under CIK 1975641. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZYBT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Zhengye Biotechnology Holding Ltd directly from SEC EDGAR.